Bickerstaff D R, Douglas D L, Burke P H, O'Doherty D P, Kanis J A
University of Sheffield Medical School, England.
J Bone Joint Surg Br. 1990 Jan;72(1):132-6. doi: 10.1302/0301-620X.72B1.2137127.
We studied nine patients with Paget's disease affecting the skull or facial bones, who were subsequently treated with either dichloromethylene diphosphonate (clodronate) or ethylene-1-hydroxy-1,1-diphosphonate (etidronate). Long-term treatment induced a clinical and biochemical improvement in eight, and this was associated with a reduction in maxillary or skull volume as assessed by quantitative stereophotogrammetry. The one patient whose disease was resistant to treatment with diphosphonate, showed no change in maxillary shape. These studies suggest that the long-term control of disease activity attained with diphosphonates, results in the improvement of skeletal deformity.
我们研究了9例患有累及颅骨或面骨的佩吉特病的患者,这些患者随后接受了二氯亚甲基二膦酸盐(氯膦酸盐)或乙烯-1-羟基-1,1-二膦酸盐(依替膦酸盐)治疗。长期治疗使8例患者在临床和生化方面得到改善,通过定量立体摄影测量法评估,这与上颌骨或颅骨体积的减小有关。1例对二膦酸盐治疗耐药的患者,上颌骨形状无变化。这些研究表明,二膦酸盐对疾病活动的长期控制可改善骨骼畸形。